Notice names this product. Fresenius Kabi USA’s Tyenne (tocilizumab-aazg) Injection is named in FDA Class I recall D-0827-2026. Your particular item is not yet verified. Compare the identifiers and exclusions in the notice before deciding whether it applies. Agency-reported hazard: Presence of particulate matter:An internal investigation at the firm found the product to contain glass particles. Identifying details: Lot: 16UI07, Exp 08/31/2028. Units affected: 4,643 20mL-vials. Status: Ongoing.
This notice names a product; your particular item is not yet verified. Compare every applicable model, serial, lot, production-date or model-year boundary below.
Tyenne (tocilizumab-aazg) Injection, 400 mg/20 mL (20 mg/mL), 20 mL vial, Rx Only, Manufactured by Fresenius Kabi USA, LLC, Lake Zurich, Illinois, 60047, NDC 65219-594-20.
Still to verify: match the label on your item with the full official notice, including any exclusions, tables and photos. Some identifiers appear only on the agency website and are absent from this data feed. A missing field does not mean all versions are affected.
If your lot or date falls outside a stated range, this notice has not established that your item is affected. This is not a finding about other recalls or product safety.
Presence of particulate matter:An internal investigation at the firm found the product to contain glass particles.
Company / brand: Fresenius Kabi USA recalls
Affected product: Tyenne (tocilizumab-aazg) Injection recall status
Official ID D-0827-2026 · Official record ↗
See all Fresenius Kabi USA recalls →
Found something wrong or missing? Report a data error.
Compiled from connected official public-domain government data. Sources last checked October 22, 2026 at 12:00 PM UTC.